GI Cancer

July 7, 2021

CheckMate 648: first-line immunotherapy as a new standard of care for advanced esophageal SCC

Nivolumab demonstrated superior overall survival versus chemotherapy in patients with previously treated esophageal squamous cell carcinoma, according to ATTRACTION-3 data. At ASCO 2021, immunotherapy efficacy data were released in the first–line setting of Checkmate […]
July 6, 2021

Updated efficacy and safety data from the CheckMate 577 trial

Nivolumab is known to demonstrate significant improvement in disease-free survival versus placebo in patients with resected stage II/III esophageal cancer with residual pathologic disease after neoadjuvant chemoradiotherapy, according to a recent publication in NEJM  […]
July 2, 2021

Final KEYNOTE 177 overall survival data for MSI-H/dMMR metastatic colorectal cancer

Pembrolizumab versus chemotherapy showed progression-free survival improvement in the second provisional analysis in patients with the tumor. The study continued until the final overall survival (OS) analysis, planned after 190 OS events […]
April 26, 2021

Neoadjuvant cemiplimab for the treatment of resectable hepatocellular carcinoma demonstrates pathological complete response rates

Neoadjuvant immunotherapy can induce pathological responses and immunological memory in different malignancies, being a potential therapy for hepatocellular carcinoma   A multi-cohort, phase II study (NCT03916627) of neoadjuvant cemiplimab (an anti-PD-1 antibody) for the treatment […]
April 20, 2021

Combination of avelumab, trastuzumab and mFOLFOX6 demonstrates clinical activity in metastatic gastroesophageal adenocarcinoma with HER2 amplification

Trastuzumab is a monoclonal antibody directed to HER2, indicated in combination with chemotherapy in 20 to 30% metastatic esophageal or gastric adenocarcinomas that overexpress HER2. However, the […]
April 5, 2021

Circulating hybrid cells are evaluated as a biomarker of treatment response in patients with rectal and esophageal cancers

The team previously demonstrated that circulating hybrid cells (CD45-positive/CK-positive) are found in high numbers in pancreatic adenocarcinoma and are better correlated with overall survival than traditional circulating tumor […]
August 10, 2020

Study evaluates degree of response associated with chemotherapy with FOLFIRINOX or Gemcitabine plus Nab-Paclitaxel in the first line in the treatment of resectable pancreatic adenocarcinoma

FOLFIRINOX and Gemcitabine plus Nab-Paclitaxel are first-line chemotherapy regimens for pancreatic cancer, but their relative efficacy in localized disease is unknown. Recently, a study published in […]
July 13, 2020

CAPP2 study evaluates aspirin use in primary prophylaxis for colorectal cancer related to Lynch syndrome

The results are from a 10-year follow-up and were published in The Lancet magazine Lynch syndrome is associated with an increased risk of colorectal cancer. Randomized […]